Kestra Private Wealth Services LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Kestra Private Wealth Services LLC trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 17.8% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 893 shares of the biopharmaceutical company’s stock after selling 193 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Regeneron Pharmaceuticals were worth $624,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of REGN. Capital International Investors grew its holdings in shares of Regeneron Pharmaceuticals by 533.0% during the 1st quarter. Capital International Investors now owns 1,683,899 shares of the biopharmaceutical company’s stock worth $1,176,069,000 after purchasing an additional 1,417,899 shares during the period. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $609,222,000. Capital World Investors raised its stake in shares of Regeneron Pharmaceuticals by 11.8% in the 1st quarter. Capital World Investors now owns 5,949,834 shares of the biopharmaceutical company’s stock valued at $4,155,451,000 after acquiring an additional 626,199 shares during the period. State Street Corp raised its stake in shares of Regeneron Pharmaceuticals by 6.8% in the 1st quarter. State Street Corp now owns 5,125,467 shares of the biopharmaceutical company’s stock valued at $3,579,729,000 after acquiring an additional 325,645 shares during the period. Finally, Dodge & Cox purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $176,271,000. 84.92% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $710.30 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.39 and a current ratio of 5.12. The stock has a market capitalization of $77.43 billion, a price-to-earnings ratio of 14.18, a PEG ratio of 2.46 and a beta of 0.29. Regeneron Pharmaceuticals, Inc. has a 1 year low of $538.01 and a 1 year high of $754.67. The stock’s fifty day moving average is $617.77 and its two-hundred day moving average is $639.33.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 EPS for the quarter, missing the consensus estimate of $9.94 by ($0.17). Regeneron Pharmaceuticals had a return on equity of 36.17% and a net margin of 39.97%. The firm had revenue of $2.86 billion during the quarter, compared to the consensus estimate of $2.80 billion. During the same quarter last year, the company posted $27.97 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was down 44.4% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 36.16 EPS for the current year.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 609 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, September 9th. The stock was sold at an average price of $741.00, for a total transaction of $451,269.00. Following the sale, the director now owns 1,082 shares of the company’s stock, valued at approximately $801,762. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Bonnie L. Bassler sold 609 shares of the stock in a transaction dated Friday, September 9th. The shares were sold at an average price of $741.00, for a total value of $451,269.00. Following the completion of the transaction, the director now owns 1,082 shares in the company, valued at approximately $801,762. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Marion Mccourt sold 1,100 shares of the stock in a transaction dated Monday, August 1st. The shares were sold at an average price of $581.53, for a total transaction of $639,683.00. Following the completion of the transaction, the executive vice president now owns 19,644 shares of the company’s stock, valued at approximately $11,423,575.32. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,740 shares of company stock worth $35,478,694. Insiders own 8.99% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, July 12th. They issued a “neutral” rating and a $625.00 target price for the company. Evercore ISI set a $635.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, June 20th. Morgan Stanley raised shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $625.00 to $851.00 in a research report on Friday, September 9th. Cowen upped their price objective on shares of Regeneron Pharmaceuticals to $655.00 in a research report on Tuesday, August 9th. Finally, Truist Financial upped their price objective on shares of Regeneron Pharmaceuticals from $718.00 to $790.00 in a research report on Friday, September 9th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $746.33.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.